Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP14 | P50281 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | KLK7 | P49862 | 1/20 | 0.39 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3363660 | 0.89 | PPARA (0.54) | CTSSPPARAMMEMMP9MMP14 | |
| SCHEMBL3361616 | 0.84 | CTSS (0.41) | CTSSPPARAMMEMMP9MMP14 | |
| SCHEMBL3362684 | 0.84 | CTSS (0.42) | CTSSPPARAMMEMMP9MMP14 | |
| SCHEMBL3365980 | 0.83 | PPARA (0.57) | CTSSPPARAPPARGKLK7KLK5 | |
| SCHEMBL3363745 | 0.82 | CTSS (0.43) | CTSSPPARAMMEKLK7KLK5 | |
| SCHEMBL3366052 | 0.82 | KLK7 (0.40) | CTSSPPARAMMP9MMP14KLK7 | |
| SCHEMBL3365604 | 0.81 | CTSS (0.38) | CTSSPPARAMMEMMP9MMP14 | |
| SCHEMBL13113845 | 0.81 | CTSS (0.38) | CTSSPPARAMMEMMP9MMP14 | |
| SCHEMBL3362567 | 0.81 | CTSS (0.40) | CTSSPPARAMMEMMP9MMP14 | |
| SCHEMBL3364320 | 0.80 | MME (0.53) | CTSSPPARAMMEMMP9MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2239268-A1 | Dipeptide derivatives | Novartis AG (CH) | 2010-10-13 | — | — | EP | disclosed |
| EP-2239268-A1 | Dipeptide derivatives | Novartis AG (CH) | 2010-10-13 | — | — | EP | disclosed |
| US-20060058242-A1 | Dipeptide derivatives | FINK CYNTHIA A | 2006-03-16 | — | — | US | disclosed |
| US-6992105-B2 | Dipeptide derivatives | NOVARTIS AG (CH) | 2006-01-31 | — | — | US | disclosed |
| US-20040235754-A1 | Dipeptide derivatives | NOVARTIS AG (CH) | 2004-11-25 | — | — | US | disclosed |
| US-6777443-B2 | Dipeptide derivatives | NOVARTIS AG (CH) | 2004-08-17 | — | — | US | disclosed |
| EP-1392720-A2 | DIPEPTIDE DERIVATIVES HAVING A N-TERMINAL 2-THIOACYL GROUP AS VASOPEPTIDASE INHIBITORS | Novartis AG (CH) | 2004-03-03 | — | — | EP | disclosed |
| US-20020183260-A1 | Dipeptide derivatives | NOVARTIS AG (CH) | 2002-12-05 | — | — | US | disclosed |
| WO-2002092622-A2 | DIPEPTIDE DERIVATIVES HAVING A N-TERMINAL 2-THIOACYL GROUP AS VASOPEPTIDASE INHIBITORS | NOVARTIS AG (CH) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183260-A1 | Dipeptide derivatives | ANPEP, ECE1, ECE2 | CTSS 623/4885PPARA 4863/4885MME 9/4885 |
| US-20060058242-A1 | Dipeptide derivatives | ANPEP, ECE2, ECE1 | CTSS 1029/4885PPARA 4773/4885MME 12/4885 |
| US-20040235754-A1 | Dipeptide derivatives | ANPEP, ECE1, ECE2 | CTSS 623/4885PPARA 4863/4885MME 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.